Study Summary
This study is designed to evaluate the safety and effectiveness of CART123 cells either alone or when combined with ruxolitinib in pediatric and young adult subjects with relapsed or refractory AML. Subjects will be enrolled into one of two treatment cohorts: subjects who will receive CART123 alone (Cohort A) or subjects who will receive CART123 in combination with ruxolitinib (Cohort B).
Want to learn more about this trial?
Request More InfoInterventions
Anti-CD123 LV redirected T cells (CART123)BIOLOGICAL
CART123 cells: lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains.
Ruxolitinib (JAKAVI®)DRUG
Ruxolitinib: an orally administered janus-activated kinase (JAK) inhibitor that selectively inhibits JAK1 and JAK2.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | United States |